Key statistics
52-week range
Open | 0.1615 |
---|---|
High | 0.1615 |
Low | 0.156 |
Bid | -- |
Offer | -- |
Previous close | 0.157 |
Average volume | 812.65k |
---|---|
Shares outstanding | 1.23bn |
Free float | 1.21bn |
P/E (TTM) | -- |
Market cap | 192.73m DKK |
EPS (TTM) | -0.0291 DKK |
Data delayed at least 15 minutes, as of Nov 21 2024 14:36 GMT.
More ▼
- Consolidated Interim report 1 January – 30 September 2024
- Konsolideret delårsrapport 1. januar – 30. september 2024
- Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) har opnået patentbeskyttelse i Japan på behandling af colorectal cancer med RNX-051.
- Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.
- Storaktionærmeddelelse - Pharma Equity Group A/S
- Major shareholder announcement - Pharma Equity Group A/S
- Ledende medarbejderes transaktioner
- Managers’ transactions
- Pharma Equity Group announces successful completion of directed issue of new shares
- Pharma Equity Group offentliggør succesfuld gennemførsel af rettet emission
More ▼